- Home
- ACIU vs DHY Comparison
ACIU vs DHY Comparison
Compare ACIU & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- DHY
- Stock Information
- Founded
- ACIU 2003
- DHY 1998
- Country
- ACIU Switzerland
- DHY United States
- Employees
- ACIU N/A
- DHY N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- DHY Finance/Investors Services
- Sector
- ACIU Health Care
- DHY Finance
- Exchange
- ACIU Nasdaq
- DHY Nasdaq
- Market Cap
- ACIU 213.3M
- DHY 216.5M
- IPO Year
- ACIU 2016
- DHY N/A
- Fundamental
- Price
- ACIU $2.97
- DHY $2.06
- Analyst Decision
- ACIU Strong Buy
- DHY
- Analyst Count
- ACIU 2
- DHY 0
- Target Price
- ACIU $10.00
- DHY N/A
- AVG Volume (30 Days)
- ACIU 266.4K
- DHY 569.1K
- Earning Date
- ACIU 11-04-2025
- DHY 01-01-0001
- Dividend Yield
- ACIU N/A
- DHY 9.10%
- EPS Growth
- ACIU N/A
- DHY N/A
- EPS
- ACIU N/A
- DHY N/A
- Revenue
- ACIU $5,482,957.00
- DHY N/A
- Revenue This Year
- ACIU N/A
- DHY N/A
- Revenue Next Year
- ACIU $1,022.98
- DHY N/A
- P/E Ratio
- ACIU N/A
- DHY N/A
- Revenue Growth
- ACIU N/A
- DHY N/A
- 52 Week Low
- ACIU $1.43
- DHY $1.77
- 52 Week High
- ACIU $4.00
- DHY $2.08
- Technical
- Relative Strength Index (RSI)
- ACIU 44.78
- DHY 51.33
- Support Level
- ACIU $2.70
- DHY $1.99
- Resistance Level
- ACIU $3.13
- DHY $2.07
- Average True Range (ATR)
- ACIU 0.21
- DHY 0.02
- MACD
- ACIU -0.05
- DHY 0.00
- Stochastic Oscillator
- ACIU 32.50
- DHY 75.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.